oalib

Publish in OALib Journal

ISSN: 2333-9721

APC: Only $99

Submit

Any time

2020 ( 2 )

2019 ( 182 )

2018 ( 333 )

2017 ( 347 )

Custom range...

Search Results: 1 - 10 of 188496 matches for " Manuel de Jesus;Amed "
All listed articles are free for downloading (OA Articles)
Page 1 /188496
Display every page Item
Efeitos do uso cr nico do amprenavir sobre a prenhez da rata albina
Mota Dunya Rodrigues,Sim?es Manuel de Jesus,Amed Abês Mahmed,Carvalho Adelino Moreira de
Revista Brasileira de Ginecologia e Obstetrícia , 2004,
Abstract: OBJETIVO: avaliar o efeito do uso cr nico do amprenavir sobre as implanta es, reabsor es, fetos, placentas e mortalidade materna e fetal da rata albina. MéTODOS: 5 grupos de ratas albinas EPM-1 Wistar, prenhes, foram usados: 2 controles, Contr1 (controle do estresse) e Contr2 (controle do veículo), e três grupos experimentais, Exper1, Exper2 e Exper3, que receberam, respectivamente, 46, 138 e 414 mg/kg de peso de solu o oral de amprenavir. Droga e veículo (propilenoglicol) foram ministrados por gavagem. Foram avaliados a evolu o ponderal, número de implanta es, de reabsor es, de fetos, de placentas e de óbitos intra-uterinos, o peso dos fetos e das placentas e malforma es maiores. Foram retirados fragmentos de pulm es, rins, fígado e intestinos para avalia o histopatológica. RESULTADOS: observou-se, no grupo Exper3, tendência a menor ganho de peso materno durante a prenhez (p=0,07), mas o amprenavir n o causou efeitos deletérios sobre o conteúdo intra-uterino. O efeito citotóxico da droga revelou-se nas análises histopatológicas de vísceras das ratas prenhes e na taxa de mortalidade materna: 50% nos grupos Exper1 e Exper2 e 70% no grupo Exper3. CONCLUS O: o amprenavir, em todas as doses administradas, mas especialmente na dose de 414 mg/kg de peso, mostrou ter efeito deletério sobre os pulm es, intestinos, rins e fígado maternos e aumentou significantemente o percentual de mortalidade materna.
Foscarnet Effects on the Rat Pregnancy Outcome Efectos del Foscarnet Sobre la Rata Pre ada
Cícero Venneri Mathias,Manuel de Jesus Sim?es,Abes Mahmed Amed,Ricardo Martins Oliveira-Filho
International Journal of Morphology , 2005,
Abstract: There are few long-term data on which to base decisions of drug management of HIV infection in pregnancy. The determination of safe medications must take into consideration the need for certain drugs and the possibility of inadvertent fetal exposure because of unplanned pregnancies. The aim of this study was to evaluate the effects of foscarnet on the entire period of rat pregnancy. Female pregnant rats were randomly assigned to four treatment groups (n = 10): one control (C) - treated with the drug vehicle (bidestilled water) and three experimental groups (E1, E2 and E3) - treated with 180, 360 or 720 mg/Kg of foscarnet, respectively. Rats were treated by gavage once daily. The treatment period extended from the first until the 20th day of pregnancy. Body weights were recorded weekly along this period. At term, the rats were sacrificed, the implantation sites and the number of fetuses and resorptions were recorded. The fetuses were evaluated for externally visible abnormalities under a stereomicroscope. No differences in body weights among the groups were observed; however, foscarnet-treated rats showed reduced fetal and placental weights. The incidence 137of resorptions and major malformations (shortening of limbs) in the E3 group was significantly raised. Foscarnet treatment during the entire period of rat pregnancy can produce definite toxic effects, mainly on the placental and fetal compartments Foscarnet es un inhibidor de la transcriptasis reversa del HIV que actúa en la síntesis del DNA. En este trabajo evaluamos los efectos crónicos del foscarnet durante la pre ez de la rata albina. Ratas pre adas fueron distribuidas aleatoriamente en cuatro grupos (n = 10 para cada grupo): uno control (C), tratadas con agua bidestilada, y tres experimentales (E1, E2 y E3), tratadas con 180, 360 o 720 mg/Kg al día de foscarnet. El fármaco y el vehículo (siempre 1 ml) fueron administrados una vez al día desde el día 0 hasta el día 20 de la gestación. Las ratas fueron pesadas semanalmente y sacrificadas al término de la pre ez. No se observaron alteraciones significativas en cuanto al incremento de peso corporal entre los grupos. Sin embargo, las ratas tratadas con foscarnet (especialmente las de los grupos E2 y E3) presentaron reducciones del peso promedio de los fetos y de las respectivas placentas. La incidencia de reabsorciones y malformaciones (acortamiento de miembros) fue significativa en el grupo E3. Se concluye que la administración de foscarnet durante toda la pre ez de la rata puede producir efectos tóxicos definidos, especialmente en los compartimient
Efeitos do uso cr?nico do amprenavir sobre a prenhez da rata albina
Mota, Dunya Rodrigues;Sim?es, Manuel de Jesus;Amed, Abês Mahmed;Carvalho, Adelino Moreira de;Oliveira-Filho, Ricardo Martins de;Kulay Júnior, Luiz;
Revista Brasileira de Ginecologia e Obstetrícia , 2004, DOI: 10.1590/S0100-72032004000300006
Abstract: objective: to evaluate the chronic effects of amprenavir on implantations, reabsorptions, fetuses, placentae, and maternal and fetal mortality in the albino rat. methods: five groups of epm-1 wistar pregnant rats were used: two controls: contr1 (control of stress) and contr2 (drug vehicle control), and 3 experimental groups that were treated once a day throughout gestation with 46mg/kg (exper1), 138mg/kg (exper2) and 414mg/kg (exper3) of oral solution of amprenavir. the drug and the vehicle (propyleneglycol) were administered by gavage. the evaluations included maternal body weight gain, number of implantations, reabsorptions, fetuses, placentae and of intrauterine deaths as well as fetal and placental mean weight and major malformations. fragments of lungs, kidneys, liver and intestines were collected and prepared for histopathological evaluation. results: exper3 group tended to show lesser maternal body weight gain during gestation (p = 0.07), but amprenavir did not affect the intrauterine contents. the cytotoxic effect of the drug was observed with regard to the histopathological analyses of pregnant rat viscerae and to the maternal mortality rate: 50% in exper1 and exper2 groups, and 70% in exper3 group. conclusion: amprenavir exerted adverse side effects on maternal lung, gut, kidney and liver, and significantly increased maternal mortality rates in all administered doses and especially at 414 mg/kg.
Foscarnet Effects on the Rat Pregnancy Outcome
Venneri Mathias,Cícero; Sim?es,Manuel de Jesus; Mahmed Amed,Abes; Martins Oliveira-Filho,Ricardo; Venneri Mathias,Camila Fernandes; dos Santos Sim?es,Ricardo; Kulay Júnior,Luiz;
International Journal of Morphology , 2005, DOI: 10.4067/S0717-95022005000200008
Abstract: there are few long-term data on which to base decisions of drug management of hiv infection in pregnancy. the determination of safe medications must take into consideration the need for certain drugs and the possibility of inadvertent fetal exposure because of unplanned pregnancies. the aim of this study was to evaluate the effects of foscarnet on the entire period of rat pregnancy. female pregnant rats were randomly assigned to four treatment groups (n = 10): one control (c) - treated with the drug vehicle (bidestilled water) and three experimental groups (e1, e2 and e3) - treated with 180, 360 or 720 mg/kg of foscarnet, respectively. rats were treated by gavage once daily. the treatment period extended from the first until the 20th day of pregnancy. body weights were recorded weekly along this period. at term, the rats were sacrificed, the implantation sites and the number of fetuses and resorptions were recorded. the fetuses were evaluated for externally visible abnormalities under a stereomicroscope. no differences in body weights among the groups were observed; however, foscarnet-treated rats showed reduced fetal and placental weights. the incidence 137of resorptions and major malformations (shortening of limbs) in the e3 group was significantly raised. foscarnet treatment during the entire period of rat pregnancy can produce definite toxic effects, mainly on the placental and fetal compartments
Efeitos do uso cr?nico do nelfinavir sobre a prenhez da rata albina: ensaio biológico
Mathias, Camila Fernandes Venneri;Mathias, Cícero Venneri;Sim?es, Ricardo Santos;Oliveira-Filho, Ricardo Martins;Amed, Abes Mahmed;Sim?es, Manuel de Jesus;Kulay Júnior, Luiz;
Revista Brasileira de Ginecologia e Obstetrícia , 2006, DOI: 10.1590/S0100-72032006000300008
Abstract: purpose: to evaluate the chronic effects of nelfinavir on body weight gain of pregnant albino rats and their concepts, as well as on the number of implantations, reabsorptions, fetuses, placentae, and maternal and fetal mortality. methods: fifty pregnant epm-1 wistar albino rats were randomly divided into five groups: two controls, contr1 (control of stress) and contr2 (drug vehicle control), and 3 experimental groups, exp40, exp120, exp360, which received 40, 120 or 360 mg/kg per day of oral solution of nelfinavir, respectively. the drug and the vehicle (distilled water) were administered twice a day (12/12 h) by gavage from the first up to the 20th day of pregnancy. after sacrifice under deep anesthesia, the following parameters were evaluated: number of implantations and reabsorptions, the weight of fetuses and placentae, and the number of intrauterine deaths as well as inspection for major malformations. data were evaluated by anova followed by the kruskal-wallis multiple comparison test. results: body weight gain during pregnancy was normal for all the groups, and no significant differences were detected between them. anova did not reveal any significant effect of nelfinavir on the studied parameters. the means of number of fetuses were: control = 9.7±0.50; nelfinavir-treated groups = 9.7±0.81. regarding the means of number of placentae and implantations, controls = 9.7±0.50; nelfinavir-treated groups = 9.6±0.78. the mean fetal weights were as follows: controls = 4.04±0.50; nelfinavir-treated groups = 3.91±0.33 g. finally, control placental weights averaged 0.64±0.02; nelfinavir-treated groups = 0.67±0.02 g. conclusion: nelfinavir was well tolerated at all the administered doses; no damage was produced on the fetuses.
High frequency heart rate variability evoked by repetitive transcranial magnetic stimulation over the medial prefrontal cortex: A preliminary investigation on brain processing of acute stressor-evoked cardiovascular reactivity  [PDF]
Eduardo Manuel Gon?alves, Saul Neves de Jesus
Open Journal of Psychiatry (OJPsych) , 2013, DOI: 10.4236/ojpsych.2013.34035
Abstract:

Introduction: Transcranial Magnetic Stimulation (TMS) is a non-invasive technique for brain stimulation. Repetitive TMS (rTMS) over the medial Prefrontal Cortex (mPFC), Broadman Area 10 (BA10) may stimulate transynaptically perigenual Anterior Cingulate Cortex (pACC, BA 33), insula, amigdala, hypothalamus and connected branches of the Autonomic Nervous System (ANS) involved in stressorevoked cardiovascular reactivity. Stressors are associated with an increase in sympathetic cardiac control, a decrease in parasympathetic control, or both, and, consequently, an increase in systolic/stroke volume, total vascular impedance/resistance and heart rate, a decrease of baroreflex sensitivity, i.e., an increase in blood pressure/arterial tension. Objectives and Aims: The present work aims, using TMS and accordingly to Gianaros modeling, based on functional neuroimaging studies and previous neuroanatomical data from animal models, to probe the connectivity of brain systems involved in stressor-evoked cardiovascular reactivity and to explore TMS potential as a tool for detection and stratification of individual differences concerning this reactivity and hemorreological risk factors correlated with the development of Coronary Heart Disease (CHD). Methods: Both subjects, a 52 years old male and a 40 years old female with previous increased Low Frequency (LF)/High Frequency (HF) Heart Rate Variability (HRV) ratios (respectively, 4.209/3.028) without decompensated cardiorespiratory symptoms, gave informed consent, and ethico-legal issues have been observed. Electroencephalographic (EEG) monitoring has been performed for safety purposes. Immediately after administration, over the mPFC, of 15 pulses of rTMS, during 60 second, with an inductive electrical current, at the stimulating coil, of 85.9 Ampère per

Effect of Lamivudine on the Rat Pregnancy Outcome Efecto de la Lamivudina en la Rata Pre ada
Rosana Dorsa Vieira Pontes,Abês Mamed Amed,Manuel Jesus Sim?es,Ricardo Martins Oliveira-Filho
International Journal of Morphology , 2005,
Abstract: Human immunodeficiency virus (HIV) infection is in growing incidence throughout the world. Due to the increasing proportion of affected women in reproductive years, the association of pregnancy with HIV infection becomes a matter of major Public Health concern. Antiretroviral drug administration turned out to be imperative during pregnancy in order to prevent the vertical transmission; accordingly, new antiretroviral drugs and anti-HIV drug associations have been tested in experimental pregnancy models before they are approved to be included in protocols for use during human pregnancy. Lamivudine is a nucleoside reverse transcriptase inhibitor currently used in association with other antiretrovirals. Since no data exist on the perinatal safety of lamivudine alone, as it is used in combination with other antiretroviral agents, and, until now, only preliminary data on the lamivudine-zidovudine combination were available, we decided to examine the gross maternal and fetal effects of lamivudine administered alone during the entire period of rat pregnancy. Forty pregnant animals were assigned at random to 4 groups (G1, G2, G3 and G4). G1 received drug vehicle; G2, G3 and G4 received daily oral doses of 5, 15 or 45 mg/kg of lamivudine, respectively. Rats were weighed on days 0, 7, 14 and 20 of pregnancy. On day 20 they were killed, their fetuses and placentas counted and weighed. The body weight gain of the rats was that normally expected for the gestation progression; no differences were noticed among the groups. In addition, no effects were observed regarding the fetal or placental number and weight, nor in the number of implantations, reabsortions, fetal or maternal deaths. In conclusion, the adverse effects reported for the lamivudine-zidovudine combination therapy may well be not due to lamivudine; further research involving a variety of strategies is needed to definitively ascertain the safety of that combination for preventing maternal-infant HIV transmission La infección por el virus de la inmunodeficiencia humana (HIV) presenta incidencia creciente en todo el mundo. Debido al aumento en la proporción de mujeres afectadas en sus a os reproductivos, el binomio embarazo/infección con HIV constituyen un tema preocupante en Salud Pública. Por esto que, la administración de fármacos antirretrovirales ha sido considerada obligatoria durante la gestación para prevenir la transmisión vertical del HIV; de este modo, nuevos fármacos y combinaciones de fármacos con actividad anti-HIV han sido desarollados y testeados en modelos de pre ez experimental, previo a su
Effect of Lamivudine on the Rat Pregnancy Outcome
Pontes,Rosana Dorsa Vieira; Amed,Abês Mamed; Sim?es,Manuel Jesus; Oliveira-Filho,Ricardo Martins; Sim?es,Ricardo Santos; Kulay Jr,Luiz;
International Journal of Morphology , 2005, DOI: 10.4067/S0717-95022005000300001
Abstract: human immunodeficiency virus (hiv) infection is in growing incidence throughout the world. due to the increasing proportion of affected women in reproductive years, the association of pregnancy with hiv infection becomes a matter of major public health concern. antiretroviral drug administration turned out to be imperative during pregnancy in order to prevent the vertical transmission; accordingly, new antiretroviral drugs and anti-hiv drug associations have been tested in experimental pregnancy models before they are approved to be included in protocols for use during human pregnancy. lamivudine is a nucleoside reverse transcriptase inhibitor currently used in association with other antiretrovirals. since no data exist on the perinatal safety of lamivudine alone, as it is used in combination with other antiretroviral agents, and, until now, only preliminary data on the lamivudine-zidovudine combination were available, we decided to examine the gross maternal and fetal effects of lamivudine administered alone during the entire period of rat pregnancy. forty pregnant animals were assigned at random to 4 groups (g1, g2, g3 and g4). g1 received drug vehicle; g2, g3 and g4 received daily oral doses of 5, 15 or 45 mg/kg of lamivudine, respectively. rats were weighed on days 0, 7, 14 and 20 of pregnancy. on day 20 they were killed, their fetuses and placentas counted and weighed. the body weight gain of the rats was that normally expected for the gestation progression; no differences were noticed among the groups. in addition, no effects were observed regarding the fetal or placental number and weight, nor in the number of implantations, reabsortions, fetal or maternal deaths. in conclusion, the adverse effects reported for the lamivudine-zidovudine combination therapy may well be not due to lamivudine; further research involving a variety of strategies is needed to definitively ascertain the safety of that combination for preventing maternal-infant hiv transmission
Tradu??o e adapta??o da vers?o revista da Escala de Avalia??o do Perfil de Atitudes acerca da Morte (EAPAM)
Loureiro,Luís Manuel de Jesus;
Revista de Enfermagem Referência , 2010,
Abstract: we present here the translation and adaptation of the death attitude profile - revised (dap-r), a revision of the dap developed by wong, reker and gesser (1994). the study was conducted with a sample of 1543 portuguese adults and shows that this instrument has good reliability and construct validity. an adjusted structure emerges between the underlying theoretical rationale for the scale and the results obtained by factor analysis.
Tradu o e adapta o da vers o revista da Escala de Avalia o do Perfil de Atitudes acerca da Morte (EAPAM) Traducción y adaptación de la versión revisada de la escala de evaluación del perfil de actitudes sobre la muerte (EAPAM) Translation and adaptation of the Revised Death Attitude Profile (DAP-R)
Luís Manuel de Jesus Loureiro
Revista de Enfermagem Referência , 2010,
Abstract: é apresentada a tradu o e adapta o da vers o Revised Death Attitude Profile ( DAP-R) na sua vers o revista por Wong, Reker e Gesser (1994). O estudo realizado numa amostra de 1543 adultos Portugueses mostra que o instrumento apresenta índices de fidelidade satisfatórios, assim como validade de construto, emergindo uma estrutura ajustada entre a deriva o racional subjacente à escala e os resultados obtidos após análise factorial. Se presenta la traducción y adaptación de la versión Revised Death Attitude Profile (DAP-R) en su versión revisada por Wong, Reker y Gesser, (1994). El estudio realizado sobre una muestra de 1543 adultos portugueses revela que el instrumento presenta niveles satisfactorios de fidelidad, así como validez de constructo, emergiendo una estructura ajustada entre la derivación racional subyacente a la escala y los resultados obtenidos tras el análisis factorial. We present here the translation and adaptation of the Death Attitude Profile - Revised (DAP-R), a revision of the DAP developed by Wong, Reker and Gesser (1994). The study was conducted with a sample of 1543 Portuguese adults and shows that this instrument has good reliability and construct validity. An adjusted structure emerges between the underlying theoretical rationale for the scale and the results obtained by factor analysis.
Page 1 /188496
Display every page Item


Home
Copyright © 2008-2017 Open Access Library. All rights reserved.